Cite
HARVARD Citation
Garrison, L. et al. (2013). Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status. Cancer. 119 (17), pp. 3113-3122. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Garrison, L. et al. (2013). Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status. Cancer. 119 (17), pp. 3113-3122. [Online].